Company Overview of Metabolic Solutions Development Company, LLC
Metabolic Solutions Development Company, LLC, a drug discovery and development company, investigates novel molecular targets and develops new therapeutics to treat metabolic diseases of aging. It provides MSDC-0160 and MSDC-0602, a therapeutic agents that treats patients diagnosed with type 2 diabetes, polycystic kidney disease, and neurodegenerative diseases that include Alzheimer’s and Parkinson’s diseases; and MSDC-new chemical entities that are non-thiazolidinediones oral mitochondrial membrane modulator insulin sensitizers for the treatment of type 2 diabetes. The company was founded in 2006 and is based in Kalamazoo, Michigan.
161 East Michigan Avenue
Kalamazoo, MI 49007
Founded in 2006
Key Executives for Metabolic Solutions Development Company, LLC
Vice President of Development
Compensation as of Fiscal Year 2014.
Metabolic Solutions Development Company, LLC Key Developments
Metabolic Solutions Development Company Announces Publication of Data Describing a New Drug Target for Diabetes
May 15 13
Metabolic Solutions Development Company announced the publication of data in the latest issue of the scientific journal PLOS ONE. on a new drug target for type 2 diabetes located in the inner mitochondrial membrane, which includes recently identified proteins that control mitochondrial pyruvate import. mTOT (mitochondrial target of thiazolidinediones) is a mitochondrial protein complex through which new anti-diabetic drugs exert their insulin sensitizing effects. Data suggest mTOT functions as a molecular sensor switch that coordinates carbohydrate, lipid, and amino acid metabolism with cell function. Recently published Phase 2b clinical data from a study in 258 type 2 diabetic patients further demonstrate modulating mTOT could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers. This new drug target may also play a role in other diseases of aging such as Alzheimer's disease and Parkinson's disease. Phase 2b clinical data published in the January 18, 2013 issue of Clinical Pharmacology & Therapeutics on the company's prototype compound, MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators, showed this new generation of insulin sensitizer met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c). The study was a 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study completed in 258 patients with type 2 diabetes. The study compared three doses of MSDC-0160 (50 mg, 100 mg and 150 mg) to maximum dose Actos (pioglitazone 45 mg) or placebo taken orally once daily for 12 weeks. All treatments were well tolerated. There were no serious adverse events attributed by investigators to the MSDC drug.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries